267 related articles for article (PubMed ID: 37498449)
1. Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors.
Aghel N; Baro Vila RC; Lui M; Hillis C; Leong DP
Curr Cardiol Rep; 2023 Sep; 25(9):941-958. PubMed ID: 37498449
[TBL] [Abstract][Full Text] [Related]
2. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Sestier M; Hillis C; Fraser G; Leong D
Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738
[TBL] [Abstract][Full Text] [Related]
3. International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.
Awan FT; Addison D; Alfraih F; Baratta SJ; Campos RN; Cugliari MS; Goh YT; Ionin VA; Mundnich S; Sverdlov AL; Tam C; Ysebaert L
Blood Adv; 2022 Sep; 6(18):5516-5525. PubMed ID: 35790105
[TBL] [Abstract][Full Text] [Related]
4. Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Hatashima A; Karami M; Shadman M
Expert Opin Pharmacother; 2022 Sep; 23(13):1545-1557. PubMed ID: 35973973
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real-world study based on the United States Food and Drug Administration Adverse Event Reporting System database.
Zhao ZX; Yang TY; Wang YH; Zhang L; Li J; Su YW
Br J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38831641
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death.
Boriani G; Menna P; Morgagni R; Minotti G; Vitolo M
Chemotherapy; 2023; 68(2):61-72. PubMed ID: 36366814
[TBL] [Abstract][Full Text] [Related]
7. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy.
Xiang S; Shen R; Xiang J; Zhu N; Gu J; Shen J; Zhang Y; Ge H
Expert Opin Drug Saf; 2024 May; 23(5):627-636. PubMed ID: 38456691
[TBL] [Abstract][Full Text] [Related]
8. Managing toxicities of Bruton tyrosine kinase inhibitors.
Lipsky A; Lamanna N
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):336-345. PubMed ID: 33275698
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Thompson MC; Mato AR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
[TBL] [Abstract][Full Text] [Related]
10. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
Palma M; Mulder TA; Österborg A
Front Immunol; 2021; 12():686768. PubMed ID: 34276674
[TBL] [Abstract][Full Text] [Related]
11. Managing Waldenström's macroglobulinemia with BTK inhibitors.
Buske C; Jurczak W; Salem JE; Dimopoulos MA
Leukemia; 2023 Jan; 37(1):35-46. PubMed ID: 36402930
[TBL] [Abstract][Full Text] [Related]
12. Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE; Brown JR
Front Immunol; 2021; 12():687458. PubMed ID: 34248972
[TBL] [Abstract][Full Text] [Related]
13. The Use of Bruton's Tyrosine Kinase Inhibitors to Treat Allergic Disorders.
Dispenza MC
Curr Treat Options Allergy; 2021; 8(3):261-273. PubMed ID: 33880321
[TBL] [Abstract][Full Text] [Related]
14. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Adverse Events Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-analysis.
Proskuriakova E; Shrestha DB; Jasaraj R; Reddy VK; Shtembari J; Raut A; Gaire S; Khosla P; Kadariya D
Clin Ther; 2024 Feb; 46(2):134-145. PubMed ID: 38102000
[TBL] [Abstract][Full Text] [Related]
16. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia:
Quartermaine C; Ghazi SM; Yasin A; Awan FT; Fradley M; Wiczer T; Kalathoor S; Ferdousi M; Krishan S; Habib A; Shaaban A; Kola-Kehinde O; Kittai AS; Rogers KA; Grever M; Ruz P; Bhat S; Dickerson T; Byrd JC; Woyach J; Addison D
JACC CardioOncol; 2023 Oct; 5(5):570-590. PubMed ID: 37969643
[TBL] [Abstract][Full Text] [Related]
18. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Pineda-Gayoso R; Alomar M; Lee DH; Fradley MG
Curr Treat Options Oncol; 2020 Jun; 21(8):67. PubMed ID: 32607825
[TBL] [Abstract][Full Text] [Related]
20. Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases.
Santoro RC; Falbo M; Levato L; Iannaccaro P; Prejanò S
Blood Coagul Fibrinolysis; 2021 Mar; 32(2):159-161. PubMed ID: 33273263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
